← Back to patent-cliff list
Direclidine
Tier C — Watch / tradeDireclidine
Nxera Pharma UK Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CHRM4
Indications (approved)：Schizophrenia, Bipolar I disorder, Mania
Regional status
US
Phase III
2025-05-08
EU
Phase III
2025-07-11
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Direclidine?
Approved indications include: Schizophrenia, Bipolar I disorder, Mania.
When does the Direclidine patent expire?
No public expiry year is available for Direclidine yet; this page updates once verified.
How do I get a quote for Direclidine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30